360Dx

Natera, BGI Genomics Ink $50M Deal to Develop, Launch Liquid Biopsy Tests in China, Elsewhere

Mar 11, 2019

NEW YORK (GenomeWeb) – Natera and BGI Genomics said today that they have signed a $50 million partnership to commercialize Natera's circulating tumor DNA Signatera minimal residual disease (MRD) test in China and to develop reproductive health tests in "select markets," all using BGI's sequencing technology and instruments.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Natera, BGI Genomics Ink $50M Deal to Develop, Launch Liquid Biopsy Tests in China, Elsewhere

To read the full story....

Breaking News

CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

Roche Nabs CE Mark for SARS-CoV-2 Quantitative Antibody Test

Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies

FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

Mount Sinai Coronavirus Antibody Test Gets NYSDOH Emergency Use Authorization for Quantitative Use

In Brief This Week: Illumina, Siemens Healthineers, Danaher, Abbott, and More

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

What's Popular?

Illumina's Stock Falls 9 Percent on Grail Acquisition Rumors

Scipher Medicine Taps Ambry Genetics to Scale Up TNF Inhibitor Response Test

Praxis Genomics Bets on Bionano Optical Maps, Sequencing to Solve Complex Rare Disease Cases

Sponsorships